Siemens Healthineers' Acquires Corindus to Enhance Robotic-Assisted Interventions

(Boston, MA. USA) to acquire the company, which offers a robotic treatment platform for the major vascular therapeutic markets, including coronary, peripheral vascular and neurovascular interventions.

Corindus develops, produces and sells robotic systems for minimally invasive procedures. These systems help doctors to precisely control guide catheters, guide wires, balloon or stent implants via integrated imaging. The physician does not have to stand at the angiography table as usual but can control the procedure with a separate controlling module and is therefore, less exposed to radiation.

Siemens Healthineers’ acquisition of Corindus meets its objective of simplifying today's challenges in everyday hospital life. Robotic assisted minimally invasive procedures have the potential to reduce treatment times, increase precision during treatment, raise standardization levels in clinical procedures and ultimately improve clinical outcomes, which is the strategic focus of Siemens Healthineers’ Advanced Therapies business segment.

The CorPath systems developed by Corindus will be used along with angiography systems sold by Siemens Healthineers that make minimally invasive treatment possible by using high-quality imaging before and during medical interventions. The company's role in image-based minimally invasive procedures is now complemented by robotic-assisted precision medicine. This expansion strengthens Siemens Healthineers’ therapy position and underlines its role as one of the leading providers of solutions along the entire treatment path. The acquisition of Corindus marks a strategically significant extension of Siemens Healthineers’ therapy business.

The future integration of Siemens Healthineers’ digitization and artificial intelligence solutions with Corindus' robotic systems offers further promising possibilities. The aim is to further increase procedure optimization in order to enable the greatest possible degree of efficiency and clinical reproducibility. Additionally, Corindus is driving forward the approval procedure for remote robotic treatment in vascular interventions. Due to the limited availability of specialists for minimally invasive procedures in many regions and the limited number of corresponding clinical facilities, remote treatment could significantly improve patients' access to treatment in the future.

“Together with Corindus, Siemens Healthineers is well-positioned to be one of the leading players in the field of robotic vascular interventions and to perform minimally invasive procedures more accurately, more quickly and more effectively. With this acquisition, we are opening up a new field for our image-guided therapies business. Together with our strong portfolio in imaging, digitalization and artificial intelligence, we are creating significant synergies to advance therapy outcomes,” said Bernd Montag, CEO of Siemens Healthineers AG.

“The interplay of exact imaging and robotic-assisted interventions will enhance both the eyes and hands of the physician, metaphorically speaking. With the addition of Corindus to our strong therapies portfolio we sharpen our procedural focus and will grow by expanding precision medicine and improving clinical outcomes. In the future, our digital and artificial intelligence-based tools will help to integrate the aspects of image-guidance and therapy even further,” said Michel Therin, President Advanced Therapies at Siemens Healthineers.

“The collaboration with Siemens Healthineers is a unique opportunity to take our business to the next level and continue our success story. Together we plan to develop next-generation solutions that further improve patient care,” said Mark Toland, President and CEO at Corindus.